AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17823448 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/d of 78% active CLA isomers (3.2 g/d: 39.2% cis‐9,trans‐11 and 38.5% trans‐10,cis‐12)
Number of subjects: 23
Study 17823448 — intervention group
Group type: COMPARATOR
Intervention: 4 g/d of safflower oil (placebo)
Number of subjects: 23
Study 17823448 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/d of 78% active CLA isomers
Number of subjects: 23
Study 15044507 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders (medicated with cyclosporin)
Number of subjects: 3
Study 15044507 — intervention group
Group type: COMPARATOR
Intervention: Controls (non-medicated subjects)
Number of subjects: 3
Study 15044507 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responders (without gingival overgrowth)
Number of subjects: 3
Study 12232756 — intervention group
Group type: EXPERIMENTAL
Intervention: full‐PCT
Number of subjects: 261
Study 12232756 — intervention group
Group type: COMPARATOR
Intervention: telephone‐PCT
Number of subjects: 261
Study 10709412 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 10709412 — intervention group
Group type: COMPARATOR
Intervention: Class I antiarrhythmic drugs
Number of subjects: 0
Study 10709412 — intervention group
Group type: EXPERIMENTAL
Intervention: Class III drugs (sotalol and amiodarone)
Number of subjects: 0
Study 10709412 — intervention group
Group type: EXPERIMENTAL
Intervention: D-sotalol
Number of subjects: 0
Study 10709412 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study 10709412 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 0
Study 7668214 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirulog
Number of subjects: 4312
Study 7668214 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 4312
Study 2183505 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic treatment with cyclosporin A (CSA) at a dosage of 2.5 mg/kg/d for 10 weeks
Number of subjects: 53
Study 2183505 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of cyclosporin A (CSA) in 1/5/10% gel and ointment
Number of subjects: 53
Study 6778754 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment (15 mg)
Number of subjects: 0
Study 6778754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6149511 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 100
Study 6149511 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranol
Number of subjects: 100
Study 31079328 — intervention group
Group type: COMPARATOR
Intervention: 0.0 mg of chromium picolinate (CrPic) supplementation per ewe (T1)
Number of subjects: 32
Study 31079328 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg of CrPic per ewe (T2)
Number of subjects: 32
Study 31079328 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 mg of CrPic per ewe (T3)
Number of subjects: 32
Study 31079328 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 mg of CrPic per ewe (T4)
Number of subjects: 32
Study 29803838 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-scope clips (OTSC)
Number of subjects: 66
Study 29803838 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (through-the-scope clips and thermal therapy plus injection with diluted adrenaline)
Number of subjects: 66
Study 26628445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive, manual-based behavioral feeding intervention for children with chronic food refusal
Number of subjects: 20
Study 26628445 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 20
Study 24961331 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated compression bandage with pressure of 20-40 mm Hg
Number of subjects: 100
Study 24961331 — intervention group
Group type: COMPARATOR
Intervention: Conventional compression bandage with pressure of 10-20 mm Hg
Number of subjects: 100
Study 22288931 — intervention group
Group type: EXPERIMENTAL
Intervention: Portex stylet
Number of subjects: 60
Study 22288931 — intervention group
Group type: COMPARATOR
Intervention: Portex single-use bougie
Number of subjects: 60
Study 22288931 — intervention group
Group type: COMPARATOR
Intervention: Frova single-use bougie
Number of subjects: 60
Study 22288931 — intervention group
Group type: COMPARATOR
Intervention: Portex reusable bougie
Number of subjects: 60
Study 20483153 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic medical record scribe
Number of subjects: 5
Study 20483153 — intervention group
Group type: COMPARATOR
Intervention: No scribe (Control)
Number of subjects: 5
Study 17919651 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitative problems group
Number of subjects: 35
Study 17919651 — intervention group
Group type: COMPARATOR
Intervention: Nonfacilitative problems group
Number of subjects: 35
Study 15707560 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel (20 EE/100 LNG)
Number of subjects: 48
Study 15707560 — intervention group
Group type: COMPARATOR
Intervention: 30 microg ethinyl estradiol combined with 150 microg levonorgestrel (30 EE/150 LNG)
Number of subjects: 48
Study 12844088 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidant/EVT bifurcated endograft
Number of subjects: 573
Study 12844088 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 573
Study 10228290 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent left vagal nerve stimulation
Number of subjects: 60
Study 8960733 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid levodopa/carbidopa (LD/CD)
Number of subjects: 23
Study 8960733 — intervention group
Group type: COMPARATOR
Intervention: Tablet levodopa/carbidopa (LD/CD)
Number of subjects: 23
Study 1662376 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal anti-CD3 antibody
Number of subjects: 143
Study 1662376 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulins
Number of subjects: 143
Study 1662376 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA DR compatibility
Number of subjects: 143
Study 1662376 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA B + DR compatibility
Number of subjects: 143
Study 1662376 — intervention group
Group type: EXPERIMENTAL
Intervention: DR incompatibilities
Number of subjects: 143
Study 1662376 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms and severity of CMV infection
Number of subjects: 143
Study 1662376 — intervention group
Group type: COMPARATOR
Intervention: Graft rejection
Number of subjects: 143
Study 7049955 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial decontamination based on sensitivity tests
Number of subjects: 35
Study 7049955 — intervention group
Group type: COMPARATOR
Intervention: Standard combination of neomycin, cephaloridin, polymyxin B or E and nystatin or amphotericin B
Number of subjects: 35
Study 30724002 — intervention group
Group type: COMPARATOR
Intervention: Licogliflozin 150 mg q.d. for 12 weeks
Number of subjects: 88
Study 30724002 — intervention group
Group type: COMPARATOR
Intervention: Licogliflozin 300 mg single dose prior to OGTT
Number of subjects: 88
Study 30724002 — intervention group
Group type: COMPARATOR
Intervention: Licogliflozin 15 mg q.d. for 14 days
Number of subjects: 88
Study 29871676 — intervention group
Group type: EXPERIMENTAL
Intervention: Care by patient navigators based on standardized operating procedures
Number of subjects: 340
Study 29871676 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 340
Study 29871676 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-related outcomes measured using questionnaires (SF 36, HADS, PAM 13, and others)
Number of subjects: 340
Study 29871676 — intervention group
Group type: EXPERIMENTAL
Intervention: Data on drug therapy, utilization of health services, and medical expenses
Number of subjects: 340
Study 27100457 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Movement-Power Training (FMPT)
Number of subjects: 161
Study 27100457 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Movement Training (FMT)
Number of subjects: 161
Study 27100457 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 161
Study 25985582 — intervention group
Group type: EXPERIMENTAL
Intervention: Letosteine (50mg thrice daily)
Number of subjects: 240
Study 25985582 — intervention group
Group type: COMPARATOR
Intervention: Ambroxol hydrochloride (30mg thrice daily)
Number of subjects: 240
Study 22053748 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximity-based hazard (PBH) modeling with varying attributes of hazard value, proximity, prevalence, and dot patterns.
Number of subjects: 447
Study 22053748 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazard value, location in or out of a clustered dot pattern, and distance.
Number of subjects: 447
Study 22053748 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of hazard value with other attributes.
Number of subjects: 447
Study 22053748 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined maps of PBH and attributes.
Number of subjects: 447
Study 18559130 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based nutrition and growth promotion intervention provided by the Senegal Nutrition Enhancement Project
Number of subjects: 0
Study 18559130 — intervention group
Group type: COMPARATOR
Intervention: Control group (villages not receiving the intervention)
Number of subjects: 0
Study 17145784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (20 mg/kg/day for 7 days)
Number of subjects: 187
Study 17145784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin-Azithromycin (15 mg/kg/day of ofloxacin for 7 days and 10 mg/kg/day of azithromycin for the first 3 days)
Number of subjects: 187
Study 17145784 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg/day for 7 days)
Number of subjects: 187
Study 17145784 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 187
Study 17145784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin-Azithromycin
Number of subjects: 187
Study 17145784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 187
Study 15807195 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (HMG-CoA reductase inhibitors)
Number of subjects: 0
Study 12113133 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication of Helicobacter pylori
Number of subjects: 0
Study 12113133 — intervention group
Group type: COMPARATOR
Intervention: Surgical intervention
Number of subjects: 0
Study 12113133 — intervention group
Group type: COMPARATOR
Intervention: Irradiation and chemotherapy
Number of subjects: 0
Study 9481021 — intervention group
Group type: EXPERIMENTAL
Intervention: CD-ROM program
Number of subjects: 24
Study 9481021 — intervention group
Group type: COMPARATOR
Intervention: Reading control group
Number of subjects: 24
Study 8056571 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertiveness Training (AT)
Number of subjects: 60
Study 8056571 — intervention group
Group type: COMPARATOR
Intervention: Alternate Treatment Control (ATC)
Number of subjects: 60
Study 2468913 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (VER, 240 mg/day)
Number of subjects: 19
Study 2468913 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (NIF, 40 mg/day)
Number of subjects: 19
Study 2468913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31726072 — intervention group
Group type: EXPERIMENTAL
Intervention: Embotrap added to contact aspiration (CA)
Number of subjects: 0
Study 31726072 — intervention group
Group type: COMPARATOR
Intervention: Contact aspiration (CA) alone
Number of subjects: 0
Study 31272379 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-Protector™
Number of subjects: 110
Study 31272379 — intervention group
Group type: COMPARATOR
Intervention: i-gel™
Number of subjects: 110
Study 28009794 — intervention group
Group type: EXPERIMENTAL
Intervention: Proclear Multifocal (Distance/Near)
Number of subjects: 16
Study 28009794 — intervention group
Group type: EXPERIMENTAL
Intervention: ACUVUE Oasys for Presbyopia
Number of subjects: 16
Study 28009794 — intervention group
Group type: EXPERIMENTAL
Intervention: Air Optix Aqua Multifocal
Number of subjects: 16
Study 28009794 — intervention group
Group type: COMPARATOR
Intervention: Control (dilated pupil without contact lens)
Number of subjects: 16
Study 25853591 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate and calcium
Number of subjects: 212
Study 25853591 — intervention group
Group type: COMPARATOR
Intervention: Heparin and protamine
Number of subjects: 212
Study 24047844 — intervention group
Group type: EXPERIMENTAL
Intervention: Papacarie Duo™
Number of subjects: 20
Study 24047844 — intervention group
Group type: COMPARATOR
Intervention: Low-speed bur
Number of subjects: 20
Study 21070775 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon and ribavirin therapy
Number of subjects: 341
Study 19269299 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity strawberry lemonade (group Strong; n=20)
Number of subjects: 100
Study 19269299 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity strawberry lemonade (group Weak; n=20)
Number of subjects: 100
Study 19269299 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemonade that increased in flavour intensity (group Increase; n=20)
Number of subjects: 100
Study 19269299 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemonade that decreased in flavour intensity (group Decrease; n=20)
Number of subjects: 100
Study 19269299 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemonade that retained a given intensity (group Same; n=20)
Number of subjects: 100
Study 16544443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric balloons
Number of subjects: 0
Study 16544443 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-reduction program adherence
Number of subjects: 0
Study 15531766 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 701
Study 15531766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study 11230065 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of consumers in clinical trial coordinating centres
Number of subjects: 62
Study 11230065 — intervention group
Group type: EXPERIMENTAL
Intervention: Input from consumers in 48 individual trials
Number of subjects: 62
Study 9242972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cafestol (61-64 mg/day)
Number of subjects: 10
Study 9242972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cafestol (60 mg/day) and kahweol (48-54 mg/day)
Number of subjects: 10
Study 8270716 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected telescoping catheter (PTC‐NB)
Number of subjects: 40
Study 8270716 — intervention group
Group type: COMPARATOR
Intervention: Protected telescoping catheter (PTC‐B)
Number of subjects: 40
Study 8270716 — intervention group
Group type: COMPARATOR
Intervention: PTC‐NB and PTC‐B
Number of subjects: 40
Study 8270716 — intervention group
Group type: COMPARATOR
Intervention: PTC‐B
Number of subjects: 40
Study 3535433 — intervention group
Group type: EXPERIMENTAL
Intervention: Nova-T
Number of subjects: 1243
Study 3535433 — intervention group
Group type: COMPARATOR
Intervention: MLCu375
Number of subjects: 1243
Study 31830094 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 13
Study 31830094 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 13
Study 28983994 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT+β2 A (daily inhalation of β2 ‐agonist terbutaline, 4 mg dose-1)
Number of subjects: 21
Study 28983994 — intervention group
Group type: COMPARATOR
Intervention: HIT (high intensity training without β2 ‐agonist)
Number of subjects: 21
Study 28983994 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT+β2 A
Number of subjects: 21
Study 28983994 — intervention group
Group type: COMPARATOR
Intervention: HIT
Number of subjects: 21
Study 26022118 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Chlorhexidine mouthwash (M-0.2% CHX)
Number of subjects: 15
Study 26022118 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Chlorhexidine mouthwash followed by tooth-brushing and 1% acetic acid (M-0.2% CHX+NP)
Number of subjects: 15
Study 26022118 — intervention group
Group type: COMPARATOR
Intervention: Sterile water mouthwash (M-WATER)
Number of subjects: 15
Study 24326928 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle endurance training (RMET)
Number of subjects: 12
Study 24326928 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RMET)
Number of subjects: 12
Study 22621750 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term adjunctive subantimicrobial dose doxycycline (SDD)
Number of subjects: 34
Study 22621750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 19546674 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mL 0.25% bupivacaine
Number of subjects: 40
Study 19546674 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study 17697223 — intervention group
Group type: EXPERIMENTAL
Intervention: TruView EVO2 laryngoscope
Number of subjects: 200
Study 17697223 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 200
Study 15336473 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined typhoid fever/HAV vaccine (3 batches)
Number of subjects: 610
Study 12575377 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi tablet (SQT)
Number of subjects: 63
Study 12575377 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study 8021539 — intervention group
Group type: EXPERIMENTAL
Intervention: Teflon cannula with a 26-gauge introducer needle and a 24-gauge cannula
Number of subjects: 20
Study 8021539 — intervention group
Group type: COMPARATOR
Intervention: 25-gauge butterfly needle
Number of subjects: 20
Study 2723122 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release potassium citrate tablets (60 meq)
Number of subjects: 18
Study 2723122 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid-release liquid potassium citrate preparation (60 meq)
Number of subjects: 18
Study 2723122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 4888876 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 30 mg twice daily
Number of subjects: 6
Study 4888876 — intervention group
Group type: COMPARATOR
Intervention: Control (Digitalis only)
Number of subjects: 6
Study 31286883 — intervention group
Group type: EXPERIMENTAL
Intervention: Supreme Laryngeal Mask Airway (SLMA)
Number of subjects: 920
Study 31286883 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Intubation (ETT)
Number of subjects: 920
Study 28408655 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaded ammunition
Number of subjects: 54
Study 28408655 — intervention group
Group type: EXPERIMENTAL
Intervention: Unleaded ammunition
Number of subjects: 54
Study 28408655 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified unleaded ammunition
Number of subjects: 54
Study 25427171 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (400 mg/d)
Number of subjects: 0
Study 25427171 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (300 mg/d)
Number of subjects: 0
Study 25427171 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (2000 mg/d)
Number of subjects: 0
Study 25427171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24278992 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir/emtricitabine/raltegravir (Switch Group)
Number of subjects: 30
Study 24278992 — intervention group
Group type: COMPARATOR
Intervention: tenofovir/emtricitabine/efavirenz (Continuation Group)
Number of subjects: 30
Study 21666939 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 300 mg daily
Number of subjects: 57
Study 21666939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 19948518 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/kg at induction of anesthesia and 0.5 mg/kg 8 hours later)
Number of subjects: 100
Study 19948518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19948518 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 100
Study 17015551 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (n = 38)
Number of subjects: 68
Study 17015551 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 30)
Number of subjects: 68
Study 17015551 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study 12711645 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine planning protocol used by each department
Number of subjects: 56
Study 12711645 — intervention group
Group type: COMPARATOR
Intervention: Larger breast size distributions
Number of subjects: 56
Study 12711645 — intervention group
Group type: COMPARATOR
Intervention: Two-dimensional contour planning
Number of subjects: 56
Study 12711645 — intervention group
Group type: EXPERIMENTAL
Intervention: Plan optimization by selecting appropriate beam parameters
Number of subjects: 56
Study 10576671 — intervention group
Group type: EXPERIMENTAL
Intervention: Road trauma film
Number of subjects: 109
Study 10576671 — intervention group
Group type: COMPARATOR
Intervention: Neutral film
Number of subjects: 109
Study 9145958 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic acid peels (68% maximum concentration) in addition to 2% hydroquinone/10% glycolic acid gel twice daily and 0.05% tretinoin cream at night.
Number of subjects: 19
Study 9145958 — intervention group
Group type: COMPARATOR
Intervention: 2% hydroquinone/10% glycolic acid gel twice daily and 0.05% tretinoin cream at night (control group).
Number of subjects: 19
Study 7942577 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 59
Study 7942577 — intervention group
Group type: COMPARATOR
Intervention: Standard term formula, standard preterm formula, experimental preterm formula
Number of subjects: 59
Study 7942577 — intervention group
Group type: COMPARATOR
Intervention: Formula feeding (all types)
Number of subjects: 59
Study 7942577 — intervention group
Group type: COMPARATOR
Intervention: All feeding groups
Number of subjects: 59
Study 3144300 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 10
Study 3144300 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormethiazole 250 mg
Number of subjects: 10